AnalystsLeonid TimashevLeonid Timashev's Stock Forecasts
AnalystsLeonid Timashev
Analyst Ranking
Top 5%
#251 out of 5527 analysts
Average Return
+16.27%
Win Rate
55%106 out of 193
Risk vs Reward
Poor
Good
Leonid Timashev's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Xencor IncXNCR | +262.90% | $7.44 | $27.00 | 2025-08-21 - 2026-08-20 | Buy |
Revolution Medicines IncRVMD | +247.03% | $59.33 | $205.89 | 2025-11-03 - 2026-10-01 | Buy |
Edgewise Therapeutics IncEWTX | +243.22% | $12.68 | $43.52 | 2025-08-08 - 2026-08-07 | Buy |
Nuvation Bio IncNUVB | +199.42% | $1.71 | $5.12 | 2025-06-17 - 2026-06-16 | Buy |
Nuvation Bio IncNUVB | +186.96% | $2.30 | $6.60 | 2025-08-08 - 2026-08-07 | Buy |
Leonid Timashev Analyst Color
Get additional color on Leonid Timashev's coverage of popular stocks
Leonid Timashev's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Alkermes PLCALKS | 8 | Buy | $56.00 | +38.14% | Reiterates | 10 days ago |
Biohaven LtdBHVN | 18 | Hold | $19.00 | +44.60% | Downgrades | 24 days ago |
Revolution Medicines IncRVMD | 7 | Buy | $251.00 | +21.91% | Maintains | a month ago |
Cormedix IncCRMD | 6 | Buy | $14.00 | +88.68% | Maintains | 2 months ago |
Legend Biotech CorpLEGN | 19 | Buy | $58.00 | +200.21% | Maintains | 2 months ago |
Axsome Therapeutics IncAXSM | 19 | Buy | $297.00 | +63.12% | Maintains | 2 months ago |
Praxis Precision Medicines IncPRAX | 2 | Buy | $462.00 | +61.03% | Maintains | 2 months ago |
Nuvation Bio IncNUVB | 8 | Buy | $20.00 | +259.71% | Maintains | 2 months ago |
Cytokinetics IncCYTK | 10 | Buy | $112.00 | +70.68% | Maintains | 2 months ago |
Cg Oncology IncCGON | 6 | Buy | $79.00 | +15.58% | Maintains | 2 months ago |
Xencor IncXNCR | 4 | Buy | $20.00 | -19.26% | Maintains | 2 months ago |
Newamsterdam Pharma Co NvNAMS | 11 | Buy | $50.00 | +106.95% | Maintains | 2 months ago |
Compass Pathways PLCCMPS | 8 | Buy | $21.00 | +75.73% | Maintains | 2 months ago |
Beone Medicines LtdONC | 10 | Buy | $450.00 | +25.43% | Maintains | 2 months ago |
Verastem IncVSTM | 3 | Buy | $14.00 | +77.22% | Maintains | 3 months ago |
Ideaya Biosciences IncIDYA | 7 | Buy | $48.00 | +26.95% | Maintains | 3 months ago |
Exelixis IncEXEL | 5 | Hold | $46.00 | -20.61% | Maintains | 3 months ago |
Edgewise Therapeutics IncEWTX | 17 | Buy | $59.00 | +45.75% | Maintains | 4 months ago |
Insmed IncINSM | 11 | Buy | $195.00 | +79.57% | Maintains | 4 months ago |
Adc Therapeutics SaADCT | 3 | Hold | $2.00 | +85.19% | Downgrades | 4 months ago |
Jasper Therapeutics IncJSPR | 2 | Hold | $3.00 | +401.67% | Maintains | 5 months ago |
Jazz Pharmaceuticals PLCJAZZ | 5 | Buy | $258.00 | +10.72% | Maintains | 5 months ago |
Brc IncBRCC | 2 | Strong Buy | $25.00 | +179.64% | Maintains | 5 months ago |
Bicycle Therapeutics PLCBCYC | 3 | Hold | $7.00 | +96.63% | Maintains | 6 months ago |
Perspective Therapeutics IncCATX | 2 | Buy | $14.00 | +414.71% | Maintains | 7 months ago |
Design Therapeutics IncDSGN | 11 | Buy | $14.00 | +14.38% | Maintains | 7 months ago |
Pyxis Oncology IncPYXS | 7 | Buy | $5.00 | +128.31% | Maintains | 9 months ago |
Incyte CorpINCY | 1 | Hold | $70.00 | N/A | Reiterates | 2 years ago |
Neubase Therapeutics IncNBSE | 1 | Hold | $20.00 | N/A | Downgrades | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.